7UKV

Wild type EGFR in complex with Lazertinib (YH25448)

Summary for 7UKV

• Entry DOI: 10.2210/pdb7ukv/pdb
• Descriptor: Epidermal growth factor receptor, N-[5-{[(4P)-4-{4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}pyrimidin-2-yl]amino}-4-methoxy-2-(morpholin-4-yl)phenyl]propanamide (3 entities in total)
• Functional Keywords: cancer, drug discovery, kinase, transferase, transferase-inhibitor complex, transferase/inhibitor
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 1
• Total formula weight: 37947.87

Authors

Beyett, T.S.,Pham, C.,Eck, M.J.,Heppner, D.E. (deposition date: 2022-04-02, release date: 2022-11-23, Last modification date: 2023-10-25)

• Primary citation: Heppner, D.E.,Wittlinger, F.,Beyett, T.S.,Shaurova, T.,Urul, D.A.,Buckley, B.,Pham, C.D.,Schaeffner, I.K.,Yang, B.,Ogboo, B.C.,May, E.W.,Schaefer, E.M.,Eck, M.J.,Laufer, S.A.,Hershberger, P.A.; Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448).; Acs Med.Chem.Lett., 13:1856-1863, 2022; PubMed: 36518696; DOI: 10.1021/acsmedchemlett.2c00213

Experimental method

X-RAY DIFFRACTION (2.4 Å)